| Gly/Gly | Gly/Arg | Arg/Arg | |
| Subjects | 221 | 277 | 106 |
| Asthma control | |||
| Controlled | 67 (42.95) | 67 (42.95) | 22 (14.10) |
| Noncontrolled | 138 (33.17) | 196 (47.12) | 82 (19.71) |
| Partially controlled | 80 (33.33) | 109 (45.42) | 51 (21.25) |
| Uncontrolled | 58 (32.95) | 87 (49.43) | 31 (17.61) |
| Features used to define asthma control | |||
| Diurnal symptoms in the previous 3 months ≥1 per week | 53 (24.2) | 82 (29.9) | 29 (27.4) |
| Asthma attacks in the previous 3 months | |||
| Yes | 64 (29.9) | 95 (35.1) | 35 (33) |
| ≥1 per week | 27 (12.2) | 33 (11.9) | 12 (11.3) |
| Nocturnal symptoms in the previous 3 months | 69 (31.5) | 99 (36.3) | 29 (27.6) |
| Activity limitation in the previous 3 months | 51 (24.3) | 70 (27) | 23 (23) |
| SABAs in the previous 3 months | |||
| >2 per week | 60 (29.8) | 76 (29.6) | 33 (32.7) |
| Use of oral steroids in the previous 3 months | |||
| Yes | 13 (6) | 20 (7.2) | 10 (9.5) |
| Short courses or continuous | 10 (4.6) | 11 (4) | 5 (4.8) |
| FEV1 <80% pred at ECRHS II | 32 (15) | 37 (14.1) | 20 (19.2) |
| Emergency department visit in the previous 12 months | 10 (4.6) | 18 (6.5) | 7 (6.6) |
| Hospitalisation in the previous 12 months | 2 (0.9) | 2 (0.7) | 0 (0) |
Data are presented as n or n (%). SABA: short-acting β2-agonist; FEV1: forced expiratory volume in 1 s; % pred: % predicted. #: n=604.